

## MULTILINEAGE DYSPLASIA IN IRAQI KURDS WITH ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE STUDY ON 105 PATIENTS

KHAMLEEN M. HASAN, MBChB \*  
NASIR A. S. AL-ALLAWI, MBChB, MSc, PhD, FRCPath\*\*  
AMEER I. A. BADI, MBChB, FIBMS \*\*\*

*Submitted 28/10/2017; accepted 31/12/2017*

### ABSTRACT

**Background:** Acute Myeloid leukemia (AML) with multilineage dysplasia (MLD) is an important subcategory of acute myeloid leukemia, which has been reported to have prognostic importance. No studies have addressed this category of AML in Iraq Kurds, so this study was initiated.

**Subject and Methods:** A total of 105 patients diagnosed as Acute Myeloid leukemia over 10 years were reassessed. They have a median age of 40 and a male: female ratio of 1.02:1. The reassessment included re-evaluation of their clinical and hematological records, as well as re-evaluation of their peripheral blood and marrow smears for multilineage dysplasia. The study also included assessing any correlations between various clinical and hematological parameters and the presence of MLD.

**Results:** Multilineage dysplasia was documented in 35.3% of cases. The dysplasia was bilineage in 23.8% and trilineage in 11.4%. The most frequent dysplastic changes were hypogranular granulocytes, pseudo-pelger-huet anomaly, and mono-lobated megakaryocytes, seen in 46.6%, 29.5% and 20.9% respectively. The dysplasia was encountered in most frequently in M5 and M6 morphological subtypes, while it was absent in the M3 subtype, a finding which was significant ( $p = 0.001$ ). When the latter subtype was excluded from evaluation, it was found that patients with MLD were less likely to have organomegaly, more likely to have leukopenia, platelets  $< 20 \times 10^9 / l$ , blast  $< 20\%$  in peripheral blood or  $< 60\%$  in bone marrow than those with no MLD, although none was significant.

**Conclusions:** Multilineage dysplasia is frequently encountered in Iraqi Kurds with AML and seen in all morphological subtypes except M3, and its presence needs to be documented in bone marrow reports on new AML cases. Further prospective studies preferably including cytogenetics to evaluate outcome in AML-MLD *versus* AML without it, needs to be initiated.

Duhok Med J 2017; 11 (2): 1-10.

**Keywords:** AML, Multilineage Dysplasia, Kurds, Iraq.

Acute myeloid leukemia (AML) is a collection of neoplastic blood disorders characterized by the clonal expansion of myeloid blasts in the bone marrow, peripheral blood or other tissues<sup>1</sup>. It is the most common acute leukemia in adults, accounting for about 80% of cases in this age group<sup>2</sup>. The annual incidence of AML is approximately 2.4 per 100,000,

and it increases progressively with age, with a median age at diagnosis of 67 years and male predominance in most countries<sup>3</sup>. Acute myeloid leukemia with multilineage dysplasia (AML-MLD) was introduced by the WHO in 2001 as a new entity and defined by presence of 20% or more peripheral blood (PB) or bone marrow (BM) blasts with morphological features

\* Senior house officer, Department of Hematology, Azdi Teaching Hospital, Duhok, Kurdistan Region, Iraq.

\*\* Professor, Department of Pathology, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

\*\*\* Lecture, Department of Pathology, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Correspondence author to: Nasir Al-Allawi, [nallawi@yahoo.com](mailto:nallawi@yahoo.com), Mobil +9647504551494

of myelodysplasia or a prior history of a myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN)<sup>4</sup>. The emphasis in this classification was mainly on morphological dysplasia, though in more recent WHO classifications, the addition of cytogenetics as a defining criterion was made, and the term AML with myelodysplasia-related changes (AML-MRC) was introduced<sup>5, 6</sup>. The importance of recognizing this entity as a distinctive entity of AML is that several studies have demonstrated that it exhibits a significantly worse clinical outcome compared to AML without associated myelodysplasia<sup>6</sup>.

In view of the absence of previous studies on multilineage dysplasia in Iraqi Kurds with AML, this study was initiated aimed at determining the frequency of this subgroup among AML patients from two teaching hospitals. Furthermore, we also aimed to determine any clinical and hematological correlations of AML of the latter subgroup.

## **MATERIALS AND METHODS**

A total of 105 patients diagnosed in the period between 2007 and 2017 based on morphology of blood film and bone marrow, supplemented by cytochemistry and/or immunophenotyping were retrospectively assessed at Azadi and Hevi teaching hospitals –Duhok, Kurdistan/Iraq. The assessment included reviewing clinical and hematological records. The peripheral blood and marrow smears were re-evaluated for morphological subtyping. Moreover, they were scrutinized for the presence and extent of dysplastic changes in erythroid, myeloid and megakaryocytic elements to determine whether they

qualify for being considered AML with multilineage dysplasia. The criteria for such designation require the presence of dysplasia in at least 50% of the cells in at least two BM cell lines. Dyserythropoietic features were defined as more than 50% dysplastic features in at least 25 erythroblasts. Dysgranulopoietic features include three or more neutrophils with hyposegmented nuclei (pseudo-Pelger–Heut anomaly), and hypogranular or agranular neutrophils (more than 50% of 10 or more neutrophils).

Dysmegakaryopoietic features were defined as three or more megakaryocytes being micronuclear, multiseparated nuclear or large mononuclear<sup>5</sup>.

The study was approved by the Kurdistan commission of medical specialization, Erbil, Kurdistan-Iraq. The statistical analysis utilized the chi square for categorical variables and the t test for the continuous ones. A *p* value of < 0.05 was considered significant.

## **RESULTS**

### **General characteristics**

The enrolled patients had ages ranging between 1.3 and 80 years (median 40 years) and included 87% adults (>15 years). There were 53 males and 52 females (male to female ratio of 1.02:1.0).

Clinically, the most common features were pallor, bleeding manifestations, fever, splenomegaly and hepatomegaly, seen at frequencies of 95.2%, 36.2%, 29.5%, 20.9%, and 13.3% respectively. Blood counts revealed anemia in 90.4%, thrombocytopenia in 98%, leukocytosis in 59%, while leucopenia was noted in 23.8%. Bone marrow was hypercellular in 88.5% of cases, normocellular in the rest.

The application of the FAB classification on our cases revealed that the most frequent subtype was M2, followed M3, and M4, while the least was M6 (Table 1).

**Table 1: AML morphological subtypes and their association with MLD.**

FAB Classification	Overall (no.105)	AML-MLD (no. 37)	p-Value
M0	12 (11.4)	5 (41.7)	0.6200
M1	18 (17.1)	7 (38.9)	0.722
M2	31(29.5)	14 (45.2)	0.169
M3	19 (18.1)	0 (0)	0.001
M3V	2 (1.9)	0 (0)	0.294
M4	17 (16.2)	6(35.3)	0.996
M5	5(4.8)	4(80.0)	0.095
M6	1 (1.0)	1 (100.0)	0.173

### AML with Myelodysplasia

Dysplastic changes noted in enrolled patients varied in frequency, it involved one cell line in 13 (12.4%), two in 25 (23.8%), and three in 12 patients (11.4%). The most frequent dysplastic change was hypogranular granulocytes seen in 46.6%, followed by pseudo- Pelger- Huet neutrophil abnormality in 29.5% and monolobed megakaryocytes in 20.9%. Other dysplastic changes are outlined in **Table 2**, and illustrated in **Figures 1 & 2**.

Out the 105 enrolled patients, 37 cases (35.3%) satisfied the criteria of MLD as set by the current study with two or more cell lines being involved. When the dysplasia was looked at in the context of morphological subtypes, the most frequent contributor was the M2 subtype (14 cases) followed by AML M1 (7 cases) then AML M4 (6 case), while 4 of the 5 cases of M5 and the only M6 showed MLD. However, no cases of M3 showed dysplasia. The

latter was highly significant ( $p=0.001$ ) (Table 1).

**Table2: Frequency of Dysplastic Findings in the enrolled AML cases.**


Finding	Total (%)
<b>Erythroid</b>	
Megaloblastic Erythroids	15 (14.2)
Erythroid multinuclearity	6 (5.7)
Inter nuclear bridge	6 (5.7)
Karyorrhexis	2 (1.9)
<b>Granulocytes</b>	
Granulocyte Nuclear Hypolobation	31 (29.5)
Hypogranularity	49 (46.6)
<b>Megakaryocytes</b>	
Multi dispersed nuclei (magakaryocytes)	19 (18)
Micro megakaryocytes	4 (3.8)
Mono lobated megakaryocytes	12 (20.9)

When the M3 subtype was excluded from evaluation, because of the absence of dysplasia, and the remaining 84 cases were analyzed, it was found that there were no significant differences in age, sex, or clinical presentation between those with MLD and those without it. Despite the lower rates of hepatomegaly (13.5% vs. 21.3%), splenomegaly (21.0% vs. 25.5%) and lymphadenopathy (8.1% vs. 14.1%), in those with dysplasia, however this was not significant ( $p$  values of 0.36, 0.68 and 0.54 respectively). As for the peripheral blood findings, and although leucopenia  $<4 \times 10^9/L$  and platelets  $<20 \times 10^9/L$  were more frequent in dysplasia patients, neither was significant ( $p=0.167$  and 0.62 respectively) (Table 3). Furthermore, peripheral blood blasts of less than 20 and bone marrow blasts less than 60 were more frequent among those with MLD, though again these were insignificant (Table 3).


## MULTILINEAGE DYSPLASIA IN IRAQI KURDS WITH AML

**Table 3: Comparison between some hematological parameters in AML with multilineage dysplasia versus those without it.**

Parameter	NON MLD No. (%)	MLD No. (%)	P Value
Hemoglobin g/dl (mean± SD)	76.97±15.54	76.22±15.50	0.192
HB <10 g/dl	39 (83)	27 (73)	0.269
WBC x10 <sup>9</sup> /L (mean ±SD)	35.42±37.14	35.37±34.40	0.995
WBC<4x10 <sup>9</sup> /L	5 (10.6)	8 (21.6)	0.167
WBC>11x10 <sup>9</sup> /L	35 (57.4)	27(73)	0.877
Platelets x10 <sup>9</sup> /L (mean ±SD)	51.31±36.58	72.43±79	0.108
PLT <150 x10 <sup>9</sup> /L	47(100)	34 (91.9)	0.163
PLT <20 x10 <sup>9</sup> /L	7 (14.9)	7 (18.9)	0.62
PB % Blasts (mean± SD)	55.75±24.85	57.33±25.42	0.588
PB % Blasts <20%	3 (8.3)	4 (12.1)	0.466
BM % of blasts (mean ±SD)	59.97±21.37	56.05±25.62	0.452
BM% of Blasts <60%	20(42.5)	17 (45.9)	0.756



**Figure 2: Shows (a) Blast + proerythroblast in the only AML-M6 case, (b) binucleated erythroid, (c) Internuclear bridge and (d) multi nucleated erythroid precursor.**



**Figure 2: Shows examples of dysplastic features in granulocytic cells and Megakaryocytes (a) Pseudo-Pelger neutrophil, (b) hypogranular neutrophil, (c) Multi separated lobes megakaryocytes and (d) monolobed megakaryocyte.**

## DISCUSSION

The general characteristics of our patients are to a great extent consistent with previous reports from Iraq<sup>7, 8</sup>. Our median age of 40 years is not unexpected since our series includes both children and adults and it has been documented that patients from this part of the world are generally younger at presentation than their Western counterparts<sup>3,6,9</sup>. The male to female ratio approaches unity, which is not unique, and has been reported by previous studies from Iraq, USA and Japan<sup>7,10,11</sup>, though most other studies report male predominance<sup>3</sup>. The distribution of morphological subtypes according to FAB classification is again consistent with previous studies from Iraq<sup>7, 8</sup>, where M2, M3 and M4 are the most

frequent subtypes. The main difference from Western studies, is that the M3 subtype is relatively more frequent in this part of the world, while its contribution in the former countries is much less<sup>9</sup>.

Multilineage Dysplasia was identified in 35.3% of cases, which is relatively intermediate between previous reports from Europe and North America, where figures ranging from 15-48% have been reported<sup>6,12-19</sup>. The variation in these figures is most likely due to variable definitions and strictness of criteria as well as the extent of investigation in different series. The lower figures focused on trilineage dysplasia and did not include bilineage ones as the new definition now necessitates, while the higher figures are

likely due to the inclusion of secondary AML as opposed to *denovo* AML, and/or the inclusion of cytogenetic studies as recommended in the new version of WHO classifications and the entity AML-MRC rather than AML-MLD as used in our study. In a developing country like ours, and in the absence of routine cytogenetic testing, identifying the latter entity seems to be more realistic at this time. One of the difficulties facing previous observers as well as the current authors and may have led to underestimation of MLD, was the overwhelming marrow infiltration by blasts in many, leaving very limited residual hemopoietic element to evaluate for dysplasia.

The failure to document any association of MLD with age is consistent with several earlier studies<sup>12, 20, 21</sup>, but is contrary to others which suggested association of MLD with older patients<sup>6, 22</sup>. From the clinical aspect, the finding of lower proportions of hepatomegaly/Splenomegaly/ Lymphadenopathy (though insignificant) is consistent with some earlier studies<sup>12</sup>, and with the notion that AML-MLD has a lower blast burden than *denovo* AML without it. The higher rates of blasts <20% in blood and <60% in marrow in those with MLD in our series is consistent with the latter notion. The association of MLD with the morphological subtypes M6, M5 and to a lesser extent in M4, M2, M1 and M0, but not with M3 is again similar to that reported in the literature<sup>12, 23</sup>.

Some investigators have found that morphological MLD on its own, is associated with worse prognosis regardless of cytogenetic changes, which supports the importance of identifying AML-MLD as

attempted in our series<sup>6,14,15,18,19</sup>. Though others, found that MLD is often linked to prognostically unfavorable AML cytogenetic profiles, but does not retain on its own independent prognostic effect<sup>13,20-22</sup>. So this topic remains much contested<sup>24</sup>, and it would have been quite interesting if the current study included evaluation of survival and remission induction data, but we were limited by the retrospective nature of the study.

In conclusion, it was found that among our patients with AML, MLD is quite frequent and further prospective studies including preferably cytogenetic and molecular studies to document the significance of this observation through assessment of overall survival, event free survival and remission induction results are necessary.

## REFERENCES

- 1- Vardiman, J. W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms. *Chemico-biological interactions*. 2010; 184(1): 16-20.
- 2- De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. *Blood cancer J*. 2016; 6(7): e441.
- 3- Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer*. 2006; 107(9): 2099-210.
- 4- Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood*. 2002; 100:2292-2302.

- 5- Arber DA, Brunning RD, Orazi A, Bain BJ, Porwit A, Vardiman JW *et al.* Acute Myeloid Leukaemia with myelodysplasia-related change In Ed Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, *et al.* WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th Edition, International agency for research on cancer. Lyon, 2008; pp.124-126.
- 6- Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, *et al.* Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. *Blood.* 2009; 113(9): 1906-1908.
- 7- Pouls RK, Shamoan RP, Muhammed NS. Clinical and haematological parameters in adult AML patients: a four year experience at Nanakaly Hospital for blood diseases. *Zanco J. Med. Sci.* 2012; 16 (3): 199-203.
- 8- Al Allawi NAS, Hilmi FA, Yahya HI, Wajdi FT, Al Saleem TI, Al-Kassab F. Acute myeloid leukaemia: Morphological subtyping and haematological findings in 214 Iraqi Adults. *J. Fac .Med. Bagdad* 1991; 33 (1): 59-71.
- 9- Hillman RS, Ault KA, Leporrier M, Rinder HM. Hematology in clinical practice. 5<sup>th</sup> edition. McGraw Hill Medical Publications. New York, 2011.
- 10- Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, *et al.* Age and acute myeloid leukemia. *Blood.* 2006; 107 (9): 3481-3485.
- 11- Strom SS, Oum R, Gbitto E, Kplola Y, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors. *Cancer.* 2012; 118(18): 4589-4596.
- 12- Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. *British J Haematol.* 1987; 66(4): 445-450.
- 13- Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, *et al.* Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. *J. Clin. Oncol.* 2003; 21(2): 256-265.
- 14- Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. *Leukemia.* 1992; 6(6): 520-525.
- 15- Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M, Ohtake S, *et al.* Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. *Int J Hematol.* 2008; 87(2): 144-151.
- 16- Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. *Critical reviews*

- in oncology/hematology*. 2004; 50(3): 197-222.
- 17-Bao L, Wang X, Ryder J, Ji M, Chen Y, Chen H, *et al*. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. *Europ J Haematol*. 2006; 77(1): 35-45.
- 18-Yanada M, Suzuki M, Kawashima K, Kiyoi H, Kinoshita T, Emi N, *et al*. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. *Europ J Haematol*. 2005; 74(5): 418-423.
- 19- Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival 2003. *Am J Clin Pathol*. 2003; 119(5): 672-80
- 20-Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, *et al*. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. *Am J Hematol*. 2014; 89(9): 874-881.
- 21-Wandt H, Schäkel U, Kroschinsky F, Prange-Krex G, Mohr B, Thiede C, *et al*. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. *Blood*. 2008; 111(4): 1855-1861.
- 22-Miesner M, Haferlach C, Bacher U, Weiss T, Maciejewski K, Kohlmann A, *et al* . Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). *Blood*. 2010; 116(15): 2742-2751.
- 23-Kahl C, Florschütz G, Müller K, Jentsch-Ullrich M, Arland S. *et al*. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. *Ann Hematol*. 1997; 75:91–94.
- 24-Vardiman J, Reichard K. Acute Myeloid Leukemia with myelodysplasia-related changes. *Am J Clin Path*. 2015; 144; 30-43.

## پوخته

**گهورینین ته خین شانیهی بین هه مه جور لدهف کوردین عیراقی بین کو په نجه شیرا خوینی ژجوری مایلویدا دژوار هه ی. فه کولینه کا پاشقه یی لسه 105 نه خوشان**

**پیشه کی:** په نجه شیرا خوینی ژجوری مایلویدا دژوار یا کو گهورینین هه مه جورین ته خین شانیهی ئیکه ژ جورین گرنگین په نجه شیرا خوینی ژجوری مایلوید کو گرنگیا وی دپاشه روژا نه ساخیی دایه. هیچ فه کولین ل هه ریما کوردستانی نه هاتینه کرن لسه رقی بابه تی له ورا نه فه کولینه هاته نه نجامدان.

**ریکین فه کولینی:** سه رجه می 105 نه خوشان هاتنه هه لسه نگانده فه کو په نجه شیرا خوینی یا دژوار هه ی ل سه رانه ری 10 سالان دا. تیکراییی ژیی وان 40 سال بوون و ریژا نیر بو می 1.02 بو 1 بو. دوباره هه لسه نگانده فه یا فان نه خوشان هاته کرن بو نومارین وان بین کلینیکی و بین خوینی هه روه سا هه لسه نگانده فییا تاقیکرنین خوینی ومه ژیی هه سستی بو گهورینین شانیهی بین هه مه جور. دقئ فه کولینی دا کومه کا هه قبه ندییا هاته دیارکرن دناقبه را داتاین کلینیکی و بین خوینی و هه بوونا گهورینین شانیهی بین هه مه جور.

**نه نجام:** گهورینین شانیهی بین هه مه جور هاتنه دیتن لدهف 35.3٪ ژ نه خوشان کو ل 23.2٪ دولایه نی بوون و ل 11.4٪ سی لایه نی بوون. نه فه گهورینه ل پرانییا جورین نه خوشیی بوون و پتر ل جورئ M5 و M6 و دیارنه بوون ل جورئ M3 و نه فه پیژانینه یا موکم بوو ژلایی زانستی فه (p=0.001). ژبلی جورئ M3 دیاریبوو کو نه خوشین گهورینین هه مه جور هه ی کیمتر تووشی مه زنبوونا هنده ک نه ندامین له شی دبن و پتر تووشی کیمبوونا ته پکین خوینی بین سپی و په روکین خوینی ب به راوردی دگه ل نه خوشین گهورینین هه مه جور نه ی.

**دهرئه نجام:** گهورینین شانیهی بین هه مه جور مشه دهینه دیتن لدهف نه خوشین په نجه شیرا خوینی جورئ مایلویدا دژوار لدهوکی وهه می جور دهینه دیتن ژبلی M3. هه بوونا گهورینا دقیت بهیته دوکومینت کرن ل تاقیکرنا مه ژیی هه سستی و پتر پیدقییه فه کولینین ئایینه یی بهینه کرن سه باره ت شانا و هه لسه نگانده دهرئه نجاما لدهف نه خوشین گهورینین، هه مه جور هه ی ببه راوردی دگه ل وان بین نه فه گهورینه نه بن.

## الخلاصة

### خلل التنسج المتعدد في الكورد العراقيين المصابين بسرطان الدم النخاعي الحاد: دراسة أسترجاعية على 105 مريض

**الخلفية والأهداف:** سرطان الدم النخاعي النقياني الحاد ذو النمو الشاذ المتعدد الطبقات هو فئة فرعية هامة من سرطان الدم النقياني الحاد، وقد تم تسجيله لأهميته كمنذير تكهنني. لم تتم أي دراسة من هذا القبيل عن هذه الفئة في إقليم كردستان، لذا بدأت هذه الدراسة.

**طرق البحث:** تم إعادة تقييم ما مجموعه 105 مريضاً تم تشخيصهم على أنها سرطان الدم النقياني الحاد على مدى 10 سنوات. ويبلغ متوسط العمر 40 سنة، ونسبة الذكور: الإناث 1.02:1. وشمل تقييم السجلات السريرية والدموية إعادة تقييم فحوصات الدم المحيطي ومسحات النخاع للبحث عن النمو الشاذ المتعدد الطبقات. وشملت الدراسة مقارنة الارتباطات بين اختلاف المعايير السريرية والدموية مع وجود النمو الشاذ المتعدد الطبقات.

**النتائج:** تم توثيق النمو الشاذ المتعدد الطبقات في 35.3% من الحالات. وكان خلل النمو الشاذ الثنائي في 23.8% و الثلاثي في 11.4%. كانت التغيرات المتضرره المتكررة هي الخلايا المحببة قليلة الفصوص، شذوذ بلكر هيو الكاذب، و النَوَّاء أحادي الفصوص، وجدت في 46.6%، 29.5% و 20.9% على التوالي. وقد وجد النمو الشاذ في معظم الأنواع الفرعية ولكن على الأرجح في M5 و M6، في حين كان مفقوداً في النوع الفرعي M3. حيث كانت النتيجة كانت احصائياً كبيرة (P = 0.001). عندما تم استبعاد النوع الفرعي الأخير من التقييم، وجد أن المرضى الذين يعانون من النمو الشاذ المتعدد الطبقات كانوا أقل احتمالاً أن يكن لديهم تضخم عضوي، ولكن من المرجح أن يكون لديهم نقص الكريات البيض، الصفائح الدموية أقل من  $20 \times 10^9$ /لتر، خلايا نخاع الاولية أقل من 20% في الدم المحيطي أو  $<60\%$  في نخاع العظم مقارنة مع أولئك الذين ليس لديهم النمو الشاذ المتعدد الطبقات.

**الاستنتاجات:** أن نسبة عالية من حالات سرطان الدم النقياني الحاد في دهوك تشهد وجود نمو شاذ متعدد الطبقات و يشمل هذا جميع الاصناف الشكلية باستثناء M3. ويتعين توثيق وجود النمو الشاذ المتعدد الطبقات في تقارير سرطان الدم النقياني الحاد، ومن الأفضل أن تشمل الدراسات المرتقبة فحوص الوراثة الخلوية لتقييم نتائج هذا السرطان الحاد ذو النمو الشاذ المتعدد الطبقات مقابل نتائج سرطان الدم الحاد بدون هذا النمو.